Ofev under the microscope: Real-World safety data for lung disease patients
NCT ID NCT04559581
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitored 425 Japanese patients with chronic fibrosing interstitial lung diseases that are getting worse over time (PF-ILD) who were prescribed Ofev capsules. Researchers tracked side effects, especially liver problems, to see how safe the drug is in everyday use. The goal was to gather real-world safety information, not to test if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib (Ofev)
What this could lead to
If successful, this study could confirm that Ofev is safe and tolerable for Japanese patients with PF-ILD, supporting its continued use to slow lung damage.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove effectiveness. Side effects like liver problems may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan